
|Articles|October 22, 2012
FDA warns of serious blood disorder resulting from abuse of Opana ER
FDA has warned patients of thrombotic thrombocytopenic purpura (TTP), a serious blood disorder, resulting from misuse of oxymorphone hydrochloride extended-release tablets (Opana ER, Endo).
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Updated COVID-19 Vaccines Effectively Protect Against Symptomatic Infection
2
Patient Interest Remains High for Pharmacist-Led Reproductive Care
3
Oral GLP-1 Aleniglipron Produces Up to 12.1% Weight Loss
4
FAQ: Where AI Use Is Now, Where It’s Headed in Pharmacy Practice
5
























